Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Radiotherapy and Temozolomide on the Tumor Vasculature and Stem Cells in Human High-grade Astrocytomas

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed primary high-grade astrocytoma, i.e. anaplastic astrocytoma or glioblastoma multiforme.~* Have a WHO performance status 0-2 and be able to undergo outpatient treatment.~* Age ≥18 years.~* No pregnant or lactating patients can be included.~* Patients must have radiographically documented measurable disease postoperatively. At least one tumor lesion must be unidimensionally measurable as follows:~  * Tumor lesion \> 10 mm on conventional MRI scan, T1-weighted series, after intravenous (i.v.) gadolinium chelate contrast.~* All diagnostic radiology studies must be performed within 28 days prior to registration.~* Absence of conditions making MRI scans impossible;~  * Cardiac pacemaker~ * Other ferromagnetic metal implants not authorised for use in MRI such as some types of cerebral aneurysm clips~ * Serious claustrophobia~ * Obesity (\> 300 lb., 140 Kg)~* Patients who are receiving corticosteroids have to receive stable or decreasing doses for at least 14 days before entering the trial.~* No prior chemotherapy for high-grade astrocytoma~* Absence of opportunistic infections making temozolomide contraindicated.~* Minimum required laboratory data:~  * Hematology:~    * Absolute granulocytes \> 1.0 x 10\^9/L~   * Platelets \> 100 x 10\^9/L~ * Biochemistry:~    * Bilirubin \< 1.5 x upper normal limit~   * INR \< 1.5~   * Serum creatinine \<1.5 x upper normal limit~* Adequate cognitive function in order to give informed consent.~* Absence of any psychological, familial or sociological condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial~* Before patient registration/randomization, written informed consent must be given according to national and local regulations.~Exclusion Criteria:~* Lack of fulfillment of inclusion criteria.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).